Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

Summary

To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).

Timeline

Start

2025-04-01

Primary completion

2027-10

Completion

2028-10

Drugs

Indications